Back
Amicus Therapeutics Inc (FOLD)
BiotechnologyFOLD · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$14.49
+0.21%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-0.09
ROE
-11.6%
Gross margin
88.5%
Debt/Equity
1.61x
Revenue growth
23.7%
Amicus Therapeutics Inc — company intelligence
Earnings surprises
Q4 2025$0.01 vs $0.09 est-94.4%
Q3 2025$0.06 vs $0.04 est+52.7%
Q2 2025$-0.07 vs $-0.12 est+41.7%
Q1 2025$-0.07 vs $-0.06 est-26.1%
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Amicus Therapeutics Inc
Weekly undervalued picks (like FOLD)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.